The massive EPS miss is largely non-cash and non-recurring, but the 22% revenue decline and 38% AlterG drop signal real operational headwinds from working capital constraints. The delayed 10-Q filing adds uncertainty. Watch for the Q2/Q3 shipment catch-up on secured AlterG orders and the ORMD-0801 Phase 2 trial start as potential catalysts. The $11.4M cash position provides a runway, but the company is burning ~$3.7M/quarter in operations.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 15 $6.70entry
- T+1 · 6mo ago −1.79%α −1.73% · $6.58
- T+5 · 6mo ago +5.22%α +4.26% · $7.05
- T+20 · 5mo ago +3.81%α +1.69% · $6.96
- T+60 · 3mo ago +12.91%α +8.40% · $7.57
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lifeward reported Q1 2026 revenue of $3.9M (down 22% YoY) and a GAAP net loss of $10.8M ($6.70/share), massively missing the single-analyst consensus EPS estimate of -$0.34. The headline miss is driven by a one-time $4.9M non-cash acquired in-process R&D charge from the Oratech acquisition, but core operations also weakened: AlterG revenue fell 38% due to working capital constraints, gross margin contracted to 34.2% from 42.2%, and the GAAP operating loss more than doubled to $10.3M. The company delayed its 10-Q filing, adding uncertainty.
Key Financial Metrics
Key Facts
- Revenue fell 22% YoY to $3.9M, missing the $5.8M consensus
- GAAP EPS of -$6.70 vs consensus -$0.34, a 958.8% miss driven by a $4.9M non-cash IPR&D charge from the Oratech acquisition
- Non-GAAP adjusted net loss was $5.1M ($3.13/share), compared to $4.6M ($5.28/share) in Q1 2025
- AlterG revenue declined 38% to $2.1M due to working capital constraints affecting sourcing and supply chain
- Gross margin contracted to 34.2% from 42.2% YoY, driven by lower production volumes, tariffs, and FX
- Cash used in operations improved to $3.7M from $5.5M YoY; cash balance rose to $11.4M from $2.2M at year-end 2025, boosted by $10M financing and $6.5M cash from Oratech acquisition
- Company delayed filing of its Q1 2026 10-Q, citing need for additional time to finalize accounting related to the strategic transaction
- ReWalk personal exoskeleton sales increased 11% to $1.6M; MyoCycle FES bike sales flat at $0.2M
- Weighted average shares outstanding nearly doubled to 1.6M from 0.87M YoY, reflecting the reverse split and equity issuance
Financial Impact
Revenue miss of ~$1.9M (33% below consensus); GAAP EPS miss of $6.36 vs consensus; operating loss doubled to $10.3M; gross margin down 800 bps
Risk Factors
- Delayed 10-Q filing may trigger Nasdaq listing compliance concerns or covenant issues
- Working capital constraints continue to impair AlterG supply chain and revenue
- Integration of Oratech and execution on the oral insulin pipeline are unproven
- Dilution from the convertible notes and warrant liabilities ($6.8M) could pressure the stock
- Revenue concentration in AlterG (54% of total) leaves the company exposed to further supply chain disruptions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295802 |
Track record
25 reports on LFWD
7 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +20.27% at T+60 after the Aug 14, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Bearish 6/10 Entry $4.06 Now $3.62 +10.84% settles Nov 20
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $4.06 Now $3.62 −10.84% settles Nov 20
- Nov 3, 202613d ago 3 Neutral 2/10 Entry $6.06 to $5.76 Now $3.62 −40.26% ▼ −4.95% −4.04% vs SPY
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $6.04 to $5.83 Now $3.62 −40.07% ▼ −3.48% −1.49% vs SPY
- Oct 8, 20265w ago 8-K Bearish 5/10 Entry $6.49 to $6.00 Now $3.62 +44.22% ▲ +7.55% +5.58% vs SPY
- Oct 1, 20266w ago 8-K Neutral 2/10 Entry $5.96 to $6.43 Now $3.62 −39.26% ▲ +7.89% +6.58% vs SPY
- Sep 25, 20267w ago DEF 14A Bearish 7/10 Entry $6.92 to $6.67 Now $3.62 +47.69% ▲ +3.61% +4.82% vs SPY
- Aug 14, 202613w ago 8-K Mixed 6/10 No price data
- Aug 14, 202613w ago Press Release Bearish 6/10 Entry $7.45 to $7.32 Now $3.62 +51.41% ▲ +1.75% +0.38% vs SPY
- Aug 11, 202614w ago EFFECT Bearish 7/10 Entry $7.57 to $7.41 Now $3.62 +52.15% ▲ +2.08% +1.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers